Inclusion Criteria:

1. Patients with histologically confirmed, advanced stage (stage IVB), recurrent, or
persistent small cell, large cell, or neuroendocrine tumor of the uterine corpus and
cervix

2. All patients must have measurable disease. Measurable disease is defined as at least
one lesion that can be accurately measured in at least one dimension (longest
dimension to be recorded). Each lesion must be > / = 20 mm when measured by
conventional techniques, including palpation, plain x-ray, CT, and MRI, or > / = 10
mm when measured by spiral CT. Biopsy confirmation is required if the lesion measures
< 30 mm or if the treating physician determines it is clinically indicated.

3. Patients must have at least one "target lesion" to be used to assess response on this
protocol as defined by RECIST. Tumors within a previously irradiated field will be
designated as "non-target" lesions unless progression is documented or a biopsy is
obtained to confirm persistence at least 90 days following completion of radiation
therapy.

4. Patients must have adequate: BONE MARROW FUNCTION: Absolute neutrophil count (ANC)
greater than or equal to 1,500/mcl and platelets greater than or equal to
100,000/mcl. RENAL FUNCTION: Creatinine less than or equal to 1.5 x institutional
upper limit normal (ULN), and measured or estimated creatinine clearance greater than
or equal to 50 ml/min. For the purpose of estimating the creatinine clearance, the
formula of Jelliffe should be utilized. HEPATIC FUNCTION: Bilirubin less than or
equal to 1.5 x ULN. SGOT and alkaline phosphatase less than or equal to 2.5 x ULN

5. Patients must have adequate: BLOOD COAGULATION PARAMETERS: PT such that international
normalized ratio (INR) is < / = 1.5 (or an in-range INR, usually between 2 and 3, if
a patient is on a stable dose of therapeutic warfarin) and a PTT < 1.2 times the
upper limit of normal. NEUROLOGIC FUNCTION: Neuropathy (sensory and motor) less than
or equal to CTCAE grade 1.

6. Patients must have signed an approved informed consent and authorization permitting
release of personal health information.

7. Patients with ECOG Performance Grade of 0 or 1

8. Patients must be free of clinically significant infection.

Exclusion Criteria:

1. Patients who have progressed through or recurred within 3 months of treatment with a
taxane agent administered on a weekly basis.

2. Patients who have previously been treated with bevacizumab or other anti-angiogenic
agents

3. Patients who are less than 4 weeks from prior chemotherapy and/or radiation therapy

4. Patients with ECOG Performance Grade of 2, 3 or 4

5. Patients with a history of other invasive malignancies, with the exception of
non-melanoma skin cancer, are excluded if there is any evidence of other malignancy
being present within the last 5 years. Patients are also excluded if their previous
cancer treatment contraindicates this protocol therapy

6. Subjects meeting any of the following criteria are ineligible for study entry: (a)
Inability to comply with study and/or follow-up procedures (b) Current, recent
(within 4 weeks of the first infusion of this study), or planned participation in an
experimental drug study other than a Genentech-sponsored bevacizumab cancer study

7. Inadequately controlled hypertension (defined as systolic blood pressure >140 or
diastolic blood pressure > 90 mmHg on antihypertensive medications)

8. Any prior history of hypertensive crisis or hypertensive encephalopathy

9. New York Heart Association (NYHA) Grade II or greater congestive heart failure

10. History of myocardial infarction or unstable angina within 6 months prior to study
enrollment

11. History of stroke or transient ischemic attack within 6 months prior to study
enrollment

12. Known metastatic cervical cancer to the central nervous system

13. Significant vascular disease (e.g., aortic aneurysm, aortic dissection)

14. Symptomatic peripheral vascular disease

15. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to study enrollment or anticipation of need for major surgical procedure during
the course of the study

16. Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to study enrollment

17. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to study enrollment

18. Serious, non-healing wound, ulcer, or bone fracture

19. Proteinuria at screening as demonstrated by urine dipstick for proteinuria > / = 2+
(patients discovered to have > / = 2+ proteinuria on dipstick urinalysis at baseline
should undergo a 24 hour urine collection and must demonstrate < / = 1g of protein in
24 hours to be eligible)

20. Known hypersensitivity to any component of bevacizumab

21. Pregnant (positive pregnancy test) or lactating

22. Patients receiving black cohosh, dong quai, valerian, St. John's wort, kava kava,
gotu kola. Patient cannot have received these medications within 14 days of therapy
start.

23. Patients with a known hypersensitivity to taxanes, Cremophor EL (polyoxyethylated
castor oil), or any component of the formulation.

24. History of hemoptysis (>/= ½ teaspoon of bright red blood per episode) within 1 month
prior to Day 1

25. Evidence of bleeding diathesis or significant coagulopathy (in the absence of
therapeutic anticoagulation)